Investing.com - Financial Markets Worldwide
🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Premarket London: BA Parent Cuts Growth Estimates; AstraZeneca Success

Published 2019-11-08, 02:20 a/m
© Reuters.
AZN
-
ICAG
-

Investing.com -- Here is a roundup of regulatory releases from the London Stock Exchange on Friday, 8th November. Please refresh for updates.

  • International Consolidated Airlines Group (LON:ICAG), the parent of British Airways, Iberia and Aer Lingus, said it’s cutting its medium-term target for earnings per share growth to at least 10% from at least 12% previously.

  • That reflects a reduced forecast for capacity growth: the group now sees available seat-kilometers rising only 3.4% a year through 2023 from a previous estimate of 6%.

  • It’s also changing the way it reports capital expenditure, stripping out any proceeds from sale of property, plant and equipment and intangible assets. As such, the new, ‘gross’ annual capex requirement is seen at an average of 4.7 billion euros ($5.2 billion), whereas the old ‘net’ capex spend had been estimated at 2.6 billion euros.

  • The estimate for levered free cash flow remained the same at 2.1 billion euros a year, while leverage is still to be contained at or below 1.8 times EBITDA.

  • Pharma group AstraZeneca (LON:AZN) reported successful Phase III trials for its roxadustat drug, used to treat anemia in patients suffering from chronic kidney disease.

  • It said it expects to make a regulatory submission for the drug to be approved in the U.S. by year-end.

    Latest comments

    Install Our App
    Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
    Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
    Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
    It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
    Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
    © 2007-2024 - Fusion Media Limited. All Rights Reserved.